Based on all these findings, SprC, a multifaceted RNA, might be identified as a metabolic signature and a potential target, which can be employed for drug discovery and development for the adjuvant treatment of drug-resistant bacterial infections. This evidence concerns the gene SPRR3 and bacterial infectious disease.